U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283835) titled 'Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin' on Dec. 06.
Brief Summary: This study aims to evaluate the efficacy and safety of CG0070 injection in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.
Study Start Date: Dec. 04
Study Type: INTERVENTIONAL
Condition:
Non Muscle Invasive Bladder Cancer
High-grade Ta/ T1 Papillary Disease Bladder Cancer
Intervention:
BIOLOGICAL: CG0070
Engineered Oncolytic Adenovirus
OTHER: DDM
Transduction-enhancing agent
Re...